Glen Havens
Psychiatry · Roswell, GANPI 1871623819
Payments from drug & device makers
Across 122 payments — averaging $22.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$709
- AbbVie$440
- Takeda Pharmaceuticals U.S.A., Inc.$420
- Lundbeck LLC$293
- Otsuka America Pharmaceutical, Inc.$251
- Corium, LLC$184
- plus $498 from 13 others
What the payments were for
- Speaking & faculty fees$50018%
- Food & beverage$2,29582%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 11 | $709 |
| AbbVie(2 entities) | 24 | $440 |
| Takeda Pharmaceuticals U.S.A., Inc. | 21 | $420 |
| Lundbeck LLC | 16 | $293 |
| Otsuka America Pharmaceutical, Inc. | 13 | $251 |
| Corium, LLC | 8 | $184 |
| Johnson & Johnson | 6 | $118 |
| Shire North American Group Inc | 5 | $101 |
| Vanda Pharmaceuticals Inc. | 3 | $58 |
| Tris Pharma Inc | 3 | $45 |
| Ironshore Pharmaceuticals Inc. | 2 | $30 |
| Bausch Health US, LLC | 2 | $29 |
| Adlon Therapeutics L.p. | 2 | $26 |
| Noven Therapeutics, LLC | 1 | $21 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $18 |
| Neos Therapeutics, LP | 1 | $17 |
| Axsome Therapeutics, Inc. | 1 | $14 |
| Jazz Pharmaceuticals Inc. | 1 | $13 |
| Neuronetics, Inc. | 1 | $8 |
How this compares
$2,795 in reported general payments places this provider in the 80th percentile of 900 psychiatry providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 20 | $33,960 |
| VyvanseLisdexamfetamine Dimesylate | 66 | $27,245 |
| Lisdexamfetamine Dimesylate | 46 | $12,094 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 99 | $7,758 |
| Bupropion XlBupropion Hcl | 212 | $6,316 |
| TrintellixVortioxetine Hydrobromide | 13 | $6,247 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 164 | $4,767 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 66 | $4,394 |
| Aripiprazole | 95 | $4,003 |
| Atomoxetine Hcl | 12 | $2,873 |
| Quetiapine Fumarate | 68 | $2,416 |
| Ziprasidone Hcl | 50 | $2,392 |
| Methylphenidate Hcl | 39 | $1,726 |
| Duloxetine Hcl | 114 | $1,667 |
| Testosterone Cypionate | 46 | $1,348 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $440 | $33,96020 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse, Trintellix | $420 | $33,49279 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 900 psychiatry providers in Georgia.
Other psychiatry in Roswell
- Michael RosenRoswell$141K
- Richard WinerRoswell$103K
- Joel KirsonRoswell$99K
- Alexandra DoddRoswell$54K
- Scot BayRoswell$26K
- Robert RiesenbergAtlanta$51.1M
- Saundra Maass-RobinsonAtlanta$11.1M
- David PurselleAtlanta$7.4M
- Maria JohnsonDecatur$5.4M
- Bethany DavisAtlanta$4.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.